ライフサイエンスコーパス: urine test

1 erences in rates of submission of a positive urine test.

2 by a history of amenorrhea and confirmed by urine test.

3 etection of renal cancer using a noninvasive urine test.

4 Pregnancy was assessed with monthly urine tests.

5 immunoassay for serum free-light-chains with urine tests.

6 5%) had NB detected by PET but not by BM and urine tests.

7 ed in interventions aimed at reducing excess urine testing.

8 % (23 positive test results out of 393 total urine tests and a total of 3986 clinic visits) vs 7.6% i

9 was defined as any opioid-positive or missed urine test, and relapse as two or more consecutive lapse

10 use during pregnancy by maternal hair test, urine test, and self-report in a sample of 691 patients

11 preliminary support for the proposal to use urine testing as a primary or secondary screening tool f

12 .73 mm; 95% CI: -5.91, 2.44) than a positive urine test at delivery (-182 g (95% CI: -295, -69.8) and

13 lification technologies may make noninvasive urine testing available for young men and for young wome

14 antenatal care (blood pressure measurement, urine tests, blood tests, and information on complicatio

15 indicating minimal or no opioid use based on urine test-confirmed self-reports.

16 2-4.5) more likely to submit an EtG-negative urine test during the 12-week intervention period, attai

17 0)more likely to submit a stimulant-negative urine test during treatment.

18 ined the national prevalence and patterns of urine testing during adult inpatient admission in the Un

19 ents with any cardiac disease, drug-positive urine test, electrolyte abnormalities, and changes in th

20 INH acetylator genotypes were determined and urine tested for INH metabolites to confirm adherence.

21 rd screening for substances of abuse and had urine tested for the presence of levamisole by liquid ch

22 Self-reported days of illicit opioid use, urine testing for illicit opioids, human immunodeficienc

23 However, urine testing for methamphetamine does not identify pati

24 Urine tests for Chlamydia organisms should not be used a

25 Urine tests for Chlamydia trachomatis permit expansion o

26 m erythropoietin (EPO) levels, and stool and urine tests for occult blood.

27 rum assays could replace Bence Jones protein urine tests for patients with light-chain multiple myelo

28 Active marijuana users, with positive urine tests for THC, showed greater activation in the fr

29 ceptor, on the prevalence of opioid-positive urine tests in African-Americans (n=77) or European-Amer

30 an fail to detect some bladder cancers, so a urine test is frequently part of the evaluation.

31 Overuse of urine testing is a driver of inappropriate antimicrobial

32 The sex bias in urine testing is not clinically supported and must be ad

33 n relapse (three consecutive opioid-positive urine tests), maximum consecutive days of heroin abstine

34 ination of 3 measures (OMT, self-report, and urine test), none of which were perfect.

35 Compulsory urine testing of prisoners for drugs, a control initiati

36 Toxicity was measured using blood and urine tests of renal, hepatic, thyroid, and bone marrow

37 atients in the routine care group missed the urine test on day 3, 4, or 5.

38 mary care populations; 14 studies of protein urine test performance among women being evaluated for s

39 rs (>/=4 of 6 months without opioid-positive urine test result [monthly and 4 times randomly] and sel

40 Opioid-positive urine test result at weeks 4, 8, and 12.

41 n should be discontinued after an unexpected urine test result can be clinically complex.

42 needed to treat to achieve a negative weekly urine test result was 3.1.

43 bsample of 2,643 (48.2%) participants with a urine test result, 34.7% of those living with HIV were u

44 up had higher proportions of opioid-positive urine test results at weeks 4 and 8 but not at week 12 (

45 ine group had fewer methamphetamine-positive urine test results compared with participants assigned t

46 use of these supplements can cause positive urine test results for metabolites of the prohibited ste

47 19-norandrostenedione is sufficient to cause urine test results positive for 19-norandrosterone, the

48 significantly higher percentage of scheduled urine test results were opiate negative (64% vs 32%; P =

49 e effective than STAR in percentage of clean urine test results, survival in treatment, and attendanc

50 me was reduction in methamphetamine-positive urine test results.

51 rs received matching vouchers independent of urine test results.

52 ype were less likely to have opioid-positive urine tests than those in the combined CT and TT genotyp

53 Primary outcomes, assessed by urine testing three times per week, were days to first h

54 Urine testing was common and frequently repeated during

55 nsitive than previously reported, but serial urine testing was useful in monitoring disease resolutio

56 e concentration in hair (which was higher if urine tests were positive) had a dose-response relations